K Pharma (4896) · InitiativeRestated
Listing on the Tokyo Stock Exchange Growth Market and Public Offering
First written in FY2023-Q3. 1 of 2 entries say "Achieved", first in FY2023-Q3. Latest entry: FY2023.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Tokyo Stock Exchange Mothers/Growth Market Listing and Growth and Talent Investment Through a Public OfferingA theme 268 companies write about · 0 as a headwind · 272 as a tailwind
The whole theme swung hardest in 2022: 24 of 91 companies on the "Worse" side.
58 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 273 threads.Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「Our shares were listed on the Tokyo Stock Exchange Growth Market on 17 October 2023.」
The company reiterates the listing on the Tokyo Stock Exchange Growth Market and completion of the public offering. - FY2023-Q3AchievedAnnual report
「We listed our shares on the Tokyo Stock Exchange Growth Market on 17 October 2023. In connection with the listing, based on resolutions of the Board of Directors dated 12 and 27 September 2023, we issued 1,680,000 new shares through a public offering, with payment completed on 16 October 2023.」
Following the end of the quarter, the company listed on 17 October 2023 and completed the issue and payment of 1,680,000 new shares through a public offering.